{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:14:28Z","timestamp":1790644468976,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH\/NCI","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00428-025-04227-x","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T01:34:03Z","timestamp":1756085643000},"page":"659-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlation between TP53\u00a0mutational status and digital quantification of p53 immunohistochemistry in mantle cell lymphoma"],"prefix":"10.1007","volume":"487","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2054-5986","authenticated-orcid":false,"given":"Mingfei","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenon","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Epstein-Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9645-4426","authenticated-orcid":false,"given":"Pallavi","family":"Galera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"4227_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","volume":"131","author":"SM Aukema","year":"2018","unstructured":"Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue MH, Rymkiewicz G, Thorns C, Hartmann S, Kluin-Nelemans H, Hermine O, Dreyling M, Klapper W (2018) Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL network. Blood 131:417\u2013420. https:\/\/doi.org\/10.1182\/blood-2017-07-797019","journal-title":"Blood"},{"key":"4227_CR2","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, James JA, Salto-Tellez M, Hamilton PW (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5","journal-title":"Sci Rep"},{"key":"4227_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZY, Won HH, Scott SN, Brannon AR, O\u2019Reilly C, Sadowska J, Casanova J, Yannes A, Hechtman JF, Yao J, Song W, Ross DS, Oultache A, Dogan S, Borsu L, Hameed M, Nafa K, Arcila ME, Ladanyi M, Berger MF (2015) Memorial Sloan Kettering-Integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 17:251\u2013264. https:\/\/doi.org\/10.1016\/j.jmoldx.2014.12.006","journal-title":"J Mol Diagn"},{"key":"4227_CR4","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1038\/emboj.2009.294","volume":"28","author":"Q Cheng","year":"2009","unstructured":"Cheng Q, Chen L, Li Z, Lane WS, Chen J (2009) ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J 28:3857\u20133867. https:\/\/doi.org\/10.1038\/emboj.2009.294","journal-title":"EMBO J"},{"key":"4227_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/gcc.22895","volume":"60","author":"C Curcio","year":"2021","unstructured":"Curcio C, Cimera R, Aryeequaye R, Rao M, Fabbri N, Zhang Y, Hameed M (2021) Poorly differentiated chordoma with whole-genome doubling evolving from a SMARCB1-deficient conventional chordoma: a case report. Genes Chromosomes Cancer 60:43\u201348. https:\/\/doi.org\/10.1002\/gcc.22895","journal-title":"Genes Chromosomes Cancer"},{"key":"4227_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41418-022-00976-3","volume":"29","author":"KC de Andrade","year":"2022","unstructured":"de Andrade KC, Lee EE, Tookmanian EM, Kesserwan CA, Manfredi JJ, Hatton JN, Loukissas JK, Zavadil J, Zhou L, Olivier M, Frone MN, Shahzada O, Longabaugh WJR, Kratz CP, Malkin D, Hainaut P, Savage SA (2022) The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death Differ 29:1071\u20131073. https:\/\/doi.org\/10.1038\/s41418-022-00976-3","journal-title":"Cell Death Differ"},{"key":"4227_CR7","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano-Almendras CP, Husby S, Freiburghaus C, Ek S, Pedersen A, Niemann C, Raty R, Brown P, Geisler CH, Andersen MK, Guldberg P, Jerkeman M, Gronbaek K (2017) TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 130:1903\u20131910. https:\/\/doi.org\/10.1182\/blood-2017-04-779736","journal-title":"Blood"},{"key":"4227_CR8","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3324\/haematol.2019.219543","volume":"105","author":"B Federmann","year":"2020","unstructured":"Federmann B, Frauenfeld L, Pertsch H, Borgmann V, Steinhilber J, Bonzheim I, Fend F, Quintanilla-Martinez L (2020) Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression. Haematologica 105:754\u2013764. https:\/\/doi.org\/10.3324\/haematol.2019.219543","journal-title":"Haematologica"},{"key":"4227_CR9","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML (2022) Mantle cell lymphoma in 2022-a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol 97:638\u2013656. https:\/\/doi.org\/10.1002\/ajh.26523","journal-title":"Am J Hematol"},{"key":"4227_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood.2024025563","volume":"145","author":"A Kumar","year":"2025","unstructured":"Kumar A, Soumerai J, Abramson JS, Barnes JA, Caron P, Chhabra S, Chabowska M, Dogan A, Falchi L, Grieve C, Haydu JE, Johnson PC, Joseph A, Kelly HE, Labarre A, Lue JK, Martignetti R, Mi J, Moskowitz A, Owens C, Plummer S, Puccio M, Salles G, Seshan V, Simkins E, Slupe N, Zhang H, Zelenetz AD (2025) Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood 145:497\u2013507. https:\/\/doi.org\/10.1182\/blood.2024025563","journal-title":"Blood"},{"key":"4227_CR11","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","volume":"10","author":"TE Lew","year":"2023","unstructured":"Lew TE, Minson A, Dickinson M, Handunnetti SM, Blombery P, Khot A, Anderson MA, Ritchie D, Tam CS, Seymour JF (2023) Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol 10:e142\u2013e154. https:\/\/doi.org\/10.1016\/S2352-3026(22)00355-6","journal-title":"Lancet Haematol"},{"key":"4227_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrm4063","volume":"16","author":"S Lykke-Andersen","year":"2015","unstructured":"Lykke-Andersen S, Jensen TH (2015) Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes. Nat Rev Mol Cell Biol 16:665\u2013677. https:\/\/doi.org\/10.1038\/nrm4063","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4227_CR13","doi-asserted-by":"publisher","unstructured":"McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L (2016) Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematol 101:e320\u2013323. https:\/\/doi.org\/10.3324\/haematol.2016.143214","DOI":"10.3324\/haematol.2016.143214"},{"key":"4227_CR14","first-page":"1001","volume":"1","author":"UM Moll","year":"2003","unstructured":"Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1:1001\u20131008","journal-title":"Mol Cancer Res"},{"key":"4227_CR15","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1080\/10428194.2022.2118529","volume":"63","author":"J Nolan","year":"2022","unstructured":"Nolan J, Murphy C, Dinneen K, Lee G, Higgins E, Bacon L, O\u2019Brien D, Flavin R, Quinn F, Vandenberghe E (2022) p53 immunohistochemistry must be confirmed by TP53 next generation sequencing for accurate risk stratification of patients with mantle cell lymphoma. Leuk Lymphoma 63:3504\u20133507. https:\/\/doi.org\/10.1080\/10428194.2022.2118529","journal-title":"Leuk Lymphoma"},{"key":"4227_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bjh.12854","volume":"166","author":"L Nordstrom","year":"2014","unstructured":"Nordstrom L, Sernbo S, Eden P, Gronbaek K, Kolstad A, Raty R, Karjalainen ML, Geisler C, Ralfkiaer E, Sundstrom C, Laurell A, Delabie J, Ehinger M, Jerkeman M, Ek S (2014) SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma\u2013a Nordic Lymphoma Group study. Br J Haematol 166:98\u2013108. https:\/\/doi.org\/10.1111\/bjh.12854","journal-title":"Br J Haematol"},{"key":"4227_CR17","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1182\/blood-2011-12-400580","volume":"119","author":"L Nygren","year":"2012","unstructured":"Nygren L, Baumgartner Wennerholm S, Klimkowska M, Christensson B, Kimby E, Sander B (2012) Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 119:4215\u20134223. https:\/\/doi.org\/10.1182\/blood-2011-12-400580","journal-title":"Blood"},{"key":"4227_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4161\/cc.2.3.394","volume":"2","author":"AL Okorokov","year":"2003","unstructured":"Okorokov AL (2003) P53 in a crosstalk between DNA repair and cell cycle checkpoints. Cell Cycle 2:233\u2013235","journal-title":"Cell Cycle"},{"key":"4227_CR19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/bjh.17023","volume":"191","author":"JM Rodrigues","year":"2020","unstructured":"Rodrigues JM, Hassan M, Freiburghaus C, Eskelund CW, Geisler C, Raty R, Kolstad A, Sundstrom C, Glimelius I, Gronbaek K, Kwiecinska A, Porwit A, Jerkeman M, Ek S (2020) p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma. Br J Haematol 191:796\u2013805. https:\/\/doi.org\/10.1111\/bjh.17023","journal-title":"Br J Haematol"},{"key":"4227_CR20","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen R, Seshan VE (2016) FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res 44:e131. https:\/\/doi.org\/10.1093\/nar\/gkw520","journal-title":"Nucleic Acids Res"},{"key":"4227_CR21","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3324\/haematol.2011.055715","volume":"97","author":"J Slotta-Huspenina","year":"2012","unstructured":"Slotta-Huspenina J, Koch I, de Leval L, Keller G, Klier M, Bink K, Kremer M, Raffeld M, Fend F, Quintanilla-Martinez L (2012) The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index. Haematologica 97:1422\u20131430. https:\/\/doi.org\/10.3324\/haematol.2011.055715","journal-title":"Haematologica"},{"key":"4227_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/gcc.22849","volume":"59","author":"L Streich","year":"2020","unstructured":"Streich L, Sukhanova M, Lu X, Chen YH, Venkataraman G, Mathews S, Zhang S, Kelemen K, Segal J, Gao J, Gordon L, Chen Q, Behdad A (2020) Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A\/B loss, and TP53 mutations: a multi-institutional study. Genes Chromosomes Cancer 59:484\u2013494. https:\/\/doi.org\/10.1002\/gcc.22849","journal-title":"Genes Chromosomes Cancer"},{"key":"4227_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","volume":"14","author":"SP Suehnholz","year":"2024","unstructured":"Suehnholz SP, Nissan MH, Zhang H, Kundra R, Nandakumar S, Lu C, Carrero S, Dhaneshwar A, Fernandez N, Xu BW, Arcila ME, Zehir A, Syed A, Brannon AR, Rudolph JE, Paraiso E, Sabbatini PJ, Levine RL, Dogan A, Gao J, Ladanyi M, Drilon A, Berger MF, Solit DB, Schultz N, Chakravarty D (2024) Quantifying the expanding landscape of clinical actionability for patients with cancer. Cancer Discov 14:49\u201365. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0467","journal-title":"Cancer Discov"},{"key":"4227_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood.2021013983","volume":"140","author":"M Tashakori","year":"2022","unstructured":"Tashakori M, Kadia T, Loghavi S, Daver N, Kanagal-Shamanna R, Pierce S, Sui D, Wei P, Khodakarami F, Tang Z, Routbort M, Bivins CA, Jabbour EJ, Medeiros LJ, Bhalla K, Kantarjian HM, Ravandi F, Khoury JD (2022) TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood 140:58\u201372. https:\/\/doi.org\/10.1182\/blood.2021013983","journal-title":"Blood"},{"key":"4227_CR25","doi-asserted-by":"publisher","unstructured":"Yan M, Sethi S, Kumar J, Kumar A, Dogan A, Galera P (2025) Leukemic presentation in nodal mantle cell lymphoma is characterized by frequent SOX11 negativity, a poor risk genomic landscape including higher TP53 alterations, and worse overall survival Haematologica. https:\/\/doi.org\/10.3324\/haematol.2024.287108","DOI":"10.3324\/haematol.2024.287108"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04227-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04227-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04227-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:30:39Z","timestamp":1759296639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04227-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["4227"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04227-x","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P.G. has received research support from Paige.AI. Z.E.P. has a consulting or advisory role with Genmab. A.K. has received research support from AbbVie, Adaptive Biotechnologies, Celgene, Pharmacyclics, Loxo\/Lily Pharmaceuticals, Seattle Genetics, Genentech, and Incyte; received honoraria from Astra Zeneca, Kite Pharmaceuticals, Janssen, Genentech, and Loxo\/Lily Pharmaceuticals; and has a consulting role with Genentech. Other authors have no conflict of interest to disclose. A.D. has received research support from Roche\/Genentech, Takeda, and Astra-Zeneca. M.Y and S.S have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Memorial Sloan Kettering Cancer Center. Consents were obtained from all patients who received molecular testing for TP53 status.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement and patient consent"}}]}}